EADV 2023: Galderma to present new data showcasing its continued leadership in dermatology Press release
Galderma reiterates its commitment to commercialize and continue developing the broadest Injectable Aesthetics portfolio on the market, following Ipsen's recent announcement Press release
Galderma achieves record 2 B USD net sales for a six-month period in H1 2023, as it continues to demonstrate leading execution and innovation capabilities in dermatology Press release
Galderma raises approximately USD 1 billion for newly issued shares in a private placement round Press release
Galderma @ WCD 2023: late-breaking phase III results for nemolizumab monotherapy in prurigo nodularis show a significant proportion of itch-free patients by week 4 Press release
WCD 2023: Galderma to present extensive data demonstrating enduring commitment to delivering innovative solutions in dermatology Press release
AMWC 2023: Data from Sculptra® Cheek Wrinkle and Alluzience® Star Studies reinforce strength of Galderma’s broad aesthetic portfolio Press release
AAD 2023: Late-Breaking Phase III results demonstrate nemolizumab’s significant impact on prurigo nodularis Press release
Galderma delivers strong FY 2022 growth driven by innovation and commercial performance Press release
